Literature DB >> 15970935

Type I interferon and cancer immunoediting.

Mark J Smyth.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15970935     DOI: 10.1038/ni0705-646

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  12 in total

1.  Fatty acid-binding protein E-FABP restricts tumor growth by promoting IFN-β responses in tumor-associated macrophages.

Authors:  Yuwen Zhang; Yanwen Sun; Enyu Rao; Fei Yan; Qiang Li; Ying Zhang; Kevin A T Silverstein; Shujun Liu; Edward Sauter; Margot P Cleary; Bing Li
Journal:  Cancer Res       Date:  2014-04-08       Impact factor: 12.701

2.  Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells.

Authors:  Mena Mansour; Peter Palese; Dmitriy Zamarin
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

Review 3.  Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.

Authors:  Serge Y Fuchs
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

4.  Inhibition of tumor growth by a newly-identified activator for epidermal fatty acid binding protein.

Authors:  Enyu Rao; Puja Singh; Xiuhong Zhai; Yan Li; Ganqian Zhu; Yuwen Zhang; Jiaqing Hao; Young-In Chi; Rhoderick E Brown; Margot P Cleary; Bing Li
Journal:  Oncotarget       Date:  2015-04-10

Review 5.  TLRs in pulmonary diseases.

Authors:  Shweta Arora; Shaniya Ahmad; Rasha Irshad; Yamini Goyal; Sahar Rafat; Neha Siddiqui; Kapil Dev; Mohammad Husain; Shakir Ali; Anant Mohan; Mansoor Ali Syed
Journal:  Life Sci       Date:  2019-07-20       Impact factor: 5.037

6.  Antiviral interferons induced by Newcastle disease virus (NDV) drive a tumor-selective apoptosis.

Authors:  Teridah Ernala Ginting; Salomo Christian; Young Othiwi Larasati; Jeremiah Suryatenggara; Ivet Marita Suriapranata; George Mathew
Journal:  Sci Rep       Date:  2019-10-22       Impact factor: 4.379

7.  Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance.

Authors:  Tatsuaki Mizutani; Nina Neugebauer; Eva M Putz; Nadine Moritz; Olivia Simma; Eva Zebedin-Brandl; Dagmar Gotthardt; Wolfgang Warsch; Eva Eckelhart; Hans-Peter Kantner; Ulrich Kalinke; Stefan Lienenklaus; Siegfried Weiss; Birgit Strobl; Mathias Müller; Veronika Sexl; Dagmar Stoiber
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

8.  USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.

Authors:  Bangxing Hong; Haiyan Li; Yong Lu; Mingjun Zhang; Yuhuan Zheng; Jianfei Qian; Qing Yi
Journal:  Mol Cancer       Date:  2014-05-31       Impact factor: 27.401

9.  Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse Melanoma Cell Growth.

Authors:  Yoshikazu Hayashi; Tomoyo Kawakubo-Yasukochi; Akiko Mizokami; Mai Hazekawa; Tomiko Yakura; Munekazu Naito; Hiroshi Takeuchi; Seiji Nakamura; Masato Hirata
Journal:  J Cancer       Date:  2017-08-02       Impact factor: 4.207

Review 10.  The intracellular signalosome of PD-L1 in cancer cells.

Authors:  David Escors; María Gato-Cañas; Miren Zuazo; Hugo Arasanz; María Jesus García-Granda; Ruth Vera; Grazyna Kochan
Journal:  Signal Transduct Target Ther       Date:  2018-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.